NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note released on Tuesday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NASDAQ NURO opened at $3.93 on Tuesday. The business has a 50 day simple moving average of $4.02 and a 200 day simple moving average of $3.86. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The stock has a market cap of $8.03 million, a price-to-earnings ratio of -0.86 and a beta of 2.29.

NeuroMetrix (NASDAQ:NURO) last posted its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. The business had revenue of $0.59 million during the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. During the same period last year, the company earned ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.